Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06309537

Chemoreflex Sensitivity in HFpEF

Chemoreflex Sensitivity in Heart Failure With Preserved Ejection Fraction

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
60 (estimated)
Sponsor
Istituto Auxologico Italiano · Academic / Other
Sex
All
Age
Healthy volunteers
Accepted

Summary

Patients with heart failure and a preserved left ventricular ejection fraction (HFpEF) almost invariably complain of exertional breathlessness. Abnormal cardiac hemodynamics with pulmonary congestion are believed to trigger dyspnea in this patients. However, some patients may complain of exertional breathlessness which seems to be out of proportion as compared with hemodynamic abnormalities. Chemoreflex sensitivity accounts for the ventilatory responses to a variety of chemical stimuli, including carbon dioxide produced by the organism during exercise. Chemoreflex sensitivity can be augmented in heart failure with reduced left ventricular ejection fraction, and an increased chemoreflex sensitivity has been linked to symptoms, neurohumoral activation, breathing disturbances, and adverse prognosis. However, the clinical correlates and implications of chemoreflex sensitivity in HFpEF have not been accurately studied. We aim to characterize chemoreflex sensitivity in patients with a diagnosis of HFpEF, and to correlate chemoreflex sensitivity with clinical and hemodynamic characteristics.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTchemoreflex evaluationthe ventilatory response to carbon dioxide and hypoxia will be assessed in study participants

Timeline

Start date
2024-10-01
Primary completion
2029-12-01
Completion
2029-12-01
First posted
2024-03-13
Last updated
2024-03-13

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT06309537. Inclusion in this directory is not an endorsement.